1、Histocompatbility of Polyurethane-silk fibroin composite with controlled release of aspirin,王维慈 Weici Wang欧阳晨曦 Chenxi Ouyang协和医院血管外科Division of vascular surgery，Union Hospital,National Natural Science Foundation of China国家自然科学基金“小口径人造血管的仿生构建与性能研究”,1,973 Pre-study Program973计划前期研究专项“非水溶性丝素粉体与功能聚合物复合小
2、口径人造血管的结构与性能研究”,2,Back ground,Embolization,Atherosclerosis,Arterial Injury,IschemicNecrosis,Back ground,Revascularization,Vascular replacement,Bypass surgery,Human vesselsMan-made graft ,Back ground,Dacron,Great vessels（10mm）,Expanded polytetrafluoroethylene，e-PTFE,Small vessels（6mm）,Mid size(610mm)
3、,Own vessels ？,Back ground,Ideal small diameter graft,Back ground,Poly-urethane(PU),Dacron,Silk,Modified Method,Tubular Fabric Reinforced,Pre-studies,3 Tier Sturcture（endometrial，middle，outer）,Pre-studies,SF-PU(1:1) Graft,Biocompatibility& Mechanical properties,Drug release system,Mechanical propert
4、ies,SF：Biocompatibility，Drug adsorption and release,PU：Biocompatibility，Mechanical properties,Tubular Fabric Reinforced3 Tier Sturcture,Silk Fibroin Powder Modified,Pre-studies,IV. Low temperature plasma technology sulfonatedSF Anti-clotting ability,Pre-studies,Drug releaseHistocompatbility of Polyu
5、rethane-silk fibroin composite with controlled release of aspirin,Present studies,Histocompatbility of Polyurethane-silk fibroin composite with controlled release of aspirin,Drug releasedSF-PU(1:1),Dog carotid arteryBy pass,ATR-FTIR,Blend film structure,Hematological Examination,1w Histological EX,4
6、w Histological EX,Drug release,Conclusion,Histocompatbility of Polyurethane-silk fibroin composite with controlled release of aspirin,Blend film structure,Pure PU,10%- SF-PU cross-section,5%-SF-PU,0%-SF-PU,ATR-FTIR of Aspirin-SF-PU (1:1) blend film,Histocompatbility of Polyurethane-silk fibroin comp
7、osite with controlled release of aspirin,Aspirin release study,37 ，relationship of aspirin release and time (means.d.,n=3),1st phase:Inhibition of thrombosis after surgery2nd phase:Reduce the riskof thrombosis,Histocompatbility of Polyurethane-silk fibroin composite with controlled release of aspiri
8、n,1w Histological Examination,Control e-PTFE 0%-SF-PU 5%-SF-PU 10%-SF-PU,（A： Completely healed ；B：Materials implanted）,Histocompatbility of Polyurethane-silk fibroin composite with controlled release of aspirin,1w Histological Examination (Tissue sections),5%-SF-PU,10%-SF-PU,0%-SF-PU,e-PTFE,A：materi
9、alB1：Pseudo-membranousB2：borderC：Inflammatory cellsD：Aspirin Crystals,Histocompatbility of Polyurethane-silk fibroin composite with controlled release of aspirin,1w Histological Examination （SEM & TEM）,A:Inflammatory cells;B:loose structure of e-PTFE, no cells,Histocompatbility of Polyurethane-silk
10、fibroin composite with controlled release of aspirin,Hematological ExaminationWhite blood cell (WBC),WBC counts of rat with different biomaterials implanted after 1 week and 4 weeks (mean s.d., n=3).(,Histocompatbility of Polyurethane-silk fibroin composite with controlled release of aspirin,Hematol
11、ogical ExaminationBlood platelet (PLT),PLT counts of rat with different biomaterials implanted in after 1 week and 4 weeks (mean s.d., *p0.05 vs.control, n=3).,Histocompatbility of Polyurethane-silk fibroin composite with controlled release of aspirin,ConclusionTraditional e-PTFE: WORST5%Aspirin-SF-
12、PU，BETTER 10%Aspirin-SF-PU，Myelosuppression?Aspirin release in SF-PU(1:1): Phase 1 and Phase 2,返 回,Histocompatbility of Polyurethane-silk fibroin composite with controlled release of aspirin,Dog carotid artery-By pass,实验分组Dog0：DacronDog1：SF-PU (1:1)Dog2：5%Aspirin-SF-PU (1:1),Dog carotid artery-By pa
13、ss,Dog1、2：Flexible textureNo bleeding,Dacron：Hard and bleeding,Dog carotid artery-By pass,4 months,Dog carotid artery-By pass,After 4 months，MRA for 0,1 Dogs,Dog0:DacronDog1:SF-PUA：graftB : occluded,Dog carotid artery-By pass,Long-term survivalDog 0：6 months，abnormal head movement； 14 months， diarrh
14、ea and dead.Dog 1、2：18 months， alive,Dog carotid artery-By pass,18 months， remove grafts,Structure keepedmechanical characterNo thrombus,Dog carotid artery-By pass,18 months， remove graftsDog 0 proximal end of Dacron graft, 8cm thrombus,Dog carotid artery-By pass,18 months， remove grafts,10%Heparin-
15、5%Aspirin-SF-PU (1:1) smooth and no thrombus ，But Anastomotic stenosis,返 回,Conclusion,Pre-study,Pre-study,present,5%Aspirin-SF-PU: best histo-compatibility, drug release system.Doc carotid artery by pass: Long-term patency rate.,Doc carotid artery by pass：choose 1:1 quality rate.SF-PU(1:1) has better bio-compatibility.,SF-PU(1:1)：acute phase has better histo-compatibility than tradional Dacron, e-PTFE, PU.,Anastomotic stenosis,Thank You !,
